side-effects and/or fear of relapse remained stable during patients' follow-up. Unexpectedly, the TABQOL scores measured at the time of inclusion of the population of prevalent patients, and at month 6 in incident cases, were not significantly different between patients taking topical corticosteroids, oral prednisone and/or immunomodulators, or immunosuppressants (P = 0Á96 and P = 0Á56, respectively). Overall, this large multicentre study provides evidence that the ABQOL score is a robust tool, sensitive to change, that assesses quality of life in patients with autoimmune bullous disease. As in many other diseases, quality-of-life questionnaires in autoimmune bullous dermatoses are poorly correlated with OSS, even in patients with high disease activity at the time of diagnosis. The close correlations between ABQOL and both DLQI and Skindex raise the question of its advantage over these scores. We have not been able to show its superiority in patients with mucosal damage. TABQOL is not sensitive to change. Unexpectedly, it does not seem to be correlated with the type of treatment.